Health
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults
PRINCETON, N.J., May 08, 2026--Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/598884d93a19fe4c5c1f8a2b16c6a7e6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/d2EVE1hUDcZch2H52bLuyg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMg--/https://media.zenfs.com/en/business-wire.com/598884d93a19fe4c5c1f8a2b16c6a7e6","width":960,"height":132},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/fLCLvaNFmoMK1PzRywhldw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTg4/https://media.zenfs.com/en/business-wire.com/598884d93a19fe4c5c1f8a2b16c6a7e6","width":640,"height":88},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/HfOaZ79zmaTlztGTLf3Fbg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA-/https://media.zenfs.com/en/business-wire.com/598884d93a19fe4c5c1f8a2b16c6a7e6","width":1200,"height":165}},"lazy":false},{"type":"text","content":"In the pivotal Phase 3 POETYK PsA clinical trials, Sotyktu demonstrated superiority compared with placebo at Week 16 across multiple endpoints, including skin and joint symptoms, with improvements in quality of life as reflected in the European Union Summary of Product Characteristics (SmPC)","length":292,"tagName":"p","attribs":{}},{"type":"text","content":"Sotyktu, a once-daily oral treatment, is the first and only tyrosine kinase 2 (TYK2) inhibitor to be approved in the European Union for this indication","length":151,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., May 08, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced that the European Commission has granted approval to Sotyktu (deucravacitinib), alone or in combination with methotrexate, for the treatment of active psoriatic arthritis (PsA) in adults who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic (DMARD) therapy. Sotyktu, a once-daily oral, selective tyrosine kinase 2 (TYK2) inhibitor, is the first TYK2 inhibitor to be approved for the treatment of active PsA in the European Union (EU).","length":583,"tagName":"p"},{"type":"text","content":""The European approval of Sotyktu for active psoriatic arthritis represents an important advancement in addressing both the skin and joint symptoms of this chronic immune-mediated disease,&qu...